

CONTACT

040 6761 1600 / 6761 1700
neuland@neulandlabs.com
neulandlabs.com

October 14, 2026

To

BSE Limited

Phiroze Jeejeebhoy Towers, 25th Floor, Dalal
Street, Mumbai – 400 001

The National Stock Exchange of India Ltd

Exchange Plaza,
Bandra Kurla Complex
Bandra (E), Mumbai – 400 001

Scrip Code: 524558

Scrip Code: NEULANLAB; Series: EQ

Ref: Our letter dated August 14, 2026 on United States Food and Drug Administration (“US FDA”) inspection at our Unit 3 manufacturing facility, located at Gaddapotharam village, Jinnaram, Sangareddy District

Dear Sir/Madam,

Sub: Intimation under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

We refer to our letter dated August 14, 2026 regarding the US FDA inspection conducted at our Unit 3 manufacturing facility, located at Gaddapotharam Village, Jinnaram, Sangareddy District, and would like to inform that the US FDA has issued an Establishment Inspection Report (EIR) against the inspection conducted from August 10, 2026 to August 14, 2026. The US FDA has concluded that this inspection is "closed".

This is for your information and records.

Thanking you

Yours Sincerely,

For **Neuland Laboratories Limited**

SARADA

BHAMIDIPATI

Digitally signed by
SARADA BHAMIDIPATI
Date: 2026.10.14
21:24:38 +05'30'

Sarada Bhamidipati
Company Secretary